Bausch + Lomb Discontinues Glaucoma Drug After Phase 2 Trial Failure

Key Facts

In a move highlighting the significant risks inherent in ophthalmic drug development, Bausch + Lomb announced disappointing results for its clinical candidate BL1107. The company reported that its Phase 2 study for the glaucoma treatment failed to meet the primary endpoint of improving visual function. Consequently, based on the totality of the study data, the firm has decided to discontinue the development of the drug immediately.

This clinical setback occurs amid a competitive landscape where specialty pharmaceutical firms are racing to innovate as older patents expire. Compared to peers like Alcon and Roche, which have been aggressively investing in retinal and glaucoma therapies, Bausch + Lomb's failure to replicate earlier positive results from smaller trials represents a hurdle for its neuroprotective pipeline. Industry analysts note that such terminations are common but costly in the high-stakes med-tech sector.

Looking ahead, investors are assessing the impact of this program termination on the company's R&D efficiency, though specific price data for BLCO was unavailable at the close of July 10, 2026. Market participants are also looking toward broader economic catalysts, such as the U.S. Balance of Trade data scheduled for release on July 7, 2026, which may influence sentiment across the healthcare and export-heavy sectors.